<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03751215</url>
  </required_header>
  <id_info>
    <org_study_id>Clareon</org_study_id>
    <nct_id>NCT03751215</nct_id>
  </id_info>
  <brief_title>Anterior Chamber Depth Variability Between Two Lenses With Different Materials</brief_title>
  <official_title>Anterior Chamber Depth (ACD) Variability Between the Clareon and Acrysof IOL: a Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prim. Prof. Dr. Oliver Findl, MBA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vienna Institute for Research in Ocular Surgery</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the change of the Anterior chamber depth (ACD) variability between the Clareon and&#xD;
      the AcrySof Intraocular lens (IOL) after implantation over 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing cataract surgery are often otherwise healthy and active with their only&#xD;
      restriction being reduced visual quality. Within the past few years, intraocular lenses&#xD;
      (IOLs) have been improved to fulfill the needs of these patients. Nowadays efforts are aiming&#xD;
      for the enhancement of the patient vision and his subjective satisfaction postoperative.&#xD;
&#xD;
      One of the best ways to accomplish this is to have a perfect intraocular lens (IOL) power&#xD;
      calculation. However, the best calculation can't help if the implanted intraocular lens (IOL)&#xD;
      changes its position after implantation.&#xD;
&#xD;
      It should be considered that an anterior chamber depth (ACD) shift, decentration, tilt or&#xD;
      rotation of an IOL could result in a reduction in visual quality. For an aspherical IOL, for&#xD;
      instance, it is essential not to be decentrated and tilted more than 0.4 mm 2 (0.8 mm 3) and&#xD;
      7° 2 (10° 3), respectively. Otherwise it will be outperformed by a spherical IOL. The&#xD;
      estimation of the post-operative intraocular lens (IOL) position and therefore the estimated&#xD;
      anterior chamber depth (ACD) is presently the main source of error (35% 4 to 42% 5) in IOL&#xD;
      power calculation and therefore for the refractive outcome of the patients after cataract&#xD;
      surgery. Presently the pre-operatively measured ACD is taken into account for several IOL&#xD;
      power calculation formulas, such as the Haigis formula, the Holladay II formula and the Olsen&#xD;
      formula.&#xD;
&#xD;
      To manage a better outcome an IOL with less postoperative influence of the anterior chamber&#xD;
      depth (ACD) is very important. To accomplish a smaller deviation after the operation of the&#xD;
      anterior chamber depth (ACD) the haptic and the material of the lens is very important. The&#xD;
      change of the anterior chamber depth (ACD) after cataract surgery can be easily measured by&#xD;
      instruments like the IOL-Master 700, AC-Master and Lenstar. It must be considered that every&#xD;
      person is different and that change of the anterior chamber depth (ACD) in different eyes can&#xD;
      cause high measurement errors. The changes in two eyes of the same patient help to minimize&#xD;
      the error. These can help to achieve a better outcome for future patients.&#xD;
&#xD;
      The hydrophobic acrylate of the Acrysof IOL has been modified to the new material in the&#xD;
      Clareon IOL. This study will evaluate whether the new Clareon has non-inferior axial&#xD;
      stability to the Acrysof.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anterior chamber depth (ACD)</measure>
    <time_frame>12 months</time_frame>
    <description>The change in anterior chamber depth (ACD) before and after cataract surgery will be measured using the IOL Master 700 and compared between the two different IOLs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distance visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Uncorrected and corrected distance visual acuity will be determined using ETDRS-charts in a distance of 4 metres and differences in refraction will be compared between the two IOLs.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Monofocal IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be implanted with two different monofocal lenses (Clareon and AcrySof) during cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract surgery</intervention_name>
    <description>During cataract surgery the patient is implanted with the monofocal IOL Clareon in one eye and the monofocal IOL AcrySof in the contralateral eye</description>
    <arm_group_label>Monofocal IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age-related cataract in both eyes&#xD;
&#xD;
          -  Scheduled for bilateral cataract surgery&#xD;
&#xD;
          -  Age 21 and older&#xD;
&#xD;
          -  Written informed consent prior to recruitment&#xD;
&#xD;
          -  Visual Acuity &gt; 0.05&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy (pregnancy test will be taken pre-operatively in women of reproductive age)&#xD;
&#xD;
          -  Any ophthalmic abnormality that could compromise visual function or the measurements&#xD;
&#xD;
          -  Presence of potential zonular weakness such as pseudoexfoliation Syndrome, history of&#xD;
             ocular trauma, previous ocular surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>105 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julius Hienert, MD</last_name>
    <phone>01/ 91021/ 57564</phone>
    <email>office@viros.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manuel Ruiß, MSc.</last_name>
    <phone>01/ 91021/ 57564</phone>
    <email>office@viros.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vienna Institute for Research in Ocular Surgery (VIROS)</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julius Hienert, MD</last_name>
      <phone>01/ 91021/ 57564</phone>
      <email>office@viros.at</email>
    </contact>
    <contact_backup>
      <last_name>Manuel Ruiß, MSc.</last_name>
      <phone>01/ 91021/ 57564</phone>
      <email>office@viros.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 20, 2018</study_first_submitted>
  <study_first_submitted_qc>November 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2018</study_first_posted>
  <last_update_submitted>April 17, 2019</last_update_submitted>
  <last_update_submitted_qc>April 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vienna Institute for Research in Ocular Surgery</investigator_affiliation>
    <investigator_full_name>Prim. Prof. Dr. Oliver Findl, MBA</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Cataract surgery</keyword>
  <keyword>Intraocular lens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

